Peptide Receptor Radionuclide Therapy by 177Lu-DOTATATE of a Secreting Cervical Paraganglioma

Clin Nucl Med. 2022 Jan 1;47(1):e71-e73. doi: 10.1097/RLU.0000000000003753.

Abstract

A 59-year-old man with a parapharyngeal paraganglioma incidentally discovered on a cervical swelling was referred to our nuclear medicine department for a morpho-metabolic assessment. An 18F-FDG PET/CT was initially performed and found an intense hypermetabolism of the lesion and a hypermetabolism of the periadrenal brown fat evoking catecholamine secretion. An additional 68Ga-DOTATOC PET/CT was performed, showing an overexpression of the somatostatin receptors of this isolated paraganglioma. After multidisciplinary discussion, a peptide receptor radionuclide therapy with somatostatin analogs using 177Lu-DOTATATE as a compassionate measure was carried out.

Publication types

  • Case Reports

MeSH terms

  • Humans
  • Male
  • Middle Aged
  • Neuroendocrine Tumors*
  • Octreotide / therapeutic use
  • Organometallic Compounds*
  • Paraganglioma* / diagnostic imaging
  • Paraganglioma* / radiotherapy
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography
  • Radioisotopes
  • Radionuclide Imaging
  • Receptors, Somatostatin

Substances

  • Organometallic Compounds
  • Radioisotopes
  • Receptors, Somatostatin
  • copper dotatate CU-64
  • Octreotide